N-Benzoyl-D-serine
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Category | Others |
Catalog number | BBF-05209 |
CAS | 86808-09-5 |
Molecular Weight | 209.20 |
Molecular Formula | C10H11NO4 |
Purity | >95% by HPLC |
Online Inquiry
Specification
Related CAS | 4582-71-2 (DL-configuration) 4877-23-0 (L-configuration) |
Synonyms | D-Serine, N-benzoyl-; Bz-D-Ser-OH; benzoyl-D-serine |
Storage | Store at -20°C |
IUPAC Name | (2R)-2-benzamido-3-hydroxypropanoic acid |
Canonical SMILES | C1=CC=C(C=C1)C(=O)NC(CO)C(=O)O |
InChI | InChI=1S/C10H11NO4/c12-6-8(10(14)15)11-9(13)7-4-2-1-3-5-7/h1-5,8,12H,6H2,(H,11,13)(H,14,15)/t8-/m1/s1 |
InChI Key | MWCDMTCWMZHVAQ-MRVPVSSYSA-N |
Properties
Boiling Point | 528.5°C at 760 mmHg |
Density | 1.347 g/cm3 |
Reference Reading
1. Glycogen phosphorylase inhibitor N-(3,5-dimethyl-Benzoyl)-N'-(β-D-glucopyranosyl)urea improves glucose tolerance under normoglycemic and diabetic conditions and rearranges hepatic metabolism
Lilla Nagy, Tibor Docsa, Magdolna Szántó, Attila Brunyánszki, Csaba Hegedűs, Judit Márton, Bálint Kónya, László Virág, László Somsák, Pál Gergely, Péter Bai PLoS One. 2013 Jul 25;8(7):e69420. doi: 10.1371/journal.pone.0069420. Print 2013.
Glycogen phosphorylase (GP) catalyzes the breakdown of glycogen and largely contributes to hepatic glucose production making GP inhibition an attractive target to modulate glucose levels in diabetes. Hereby we present the metabolic effects of a novel, potent, glucose-based GP inhibitor (KB228) tested in vitro and in vivo under normoglycemic and diabetic conditions. KB228 administration enhanced glucose sensitivity in chow-fed and obese, diabetic mice that was a result of higher hepatic glucose uptake. Besides improved glucose sensitivity, we have observed further unexpected metabolic rearrangements. KB228 administration increased oxygen consumption that was probably due to the overexpression of uncoupling protein-2 (UCP2) that was observed in animal and cellular models. Furthermore, KB228 treatment induced mammalian target of rapamycin complex 2 (mTORC2) in mice. Our data demonstrate that glucose based GP inhibitors are capable of reducing glucose levels in mice under normo and hyperglycemic conditions. Moreover, these GP inhibitors induce accommodation in addition to GP inhibition--such as enhanced mitochondrial oxidation and mTORC2 signaling--to cope with the glucose influx and increased glycogen deposition in the cells, however the molecular mechanism of accommodation is unexplored.
2. Ethyl esters of N-(3- and N-(4-amidinobenzoyl)(-L-)amino acids: synthesis and antiproteolytic activity towards bovine trypsin and porcine pancreatic kallikrein
R Ferroni, E Menegatti, P Orlandini, S Scalia, M Guarneri, M Bolognesi, P Ascenzi Farmaco Sci. 1985 Oct;40(10):717-29.
Ethyl esters of N-(3- and N-(4-amidinobenzoyl)(-L-)amino acids (namely, glycine, alanine, valine, leucine and phenylalanine) were synthesized and their inhibitory effect on the bovine trypsin and porcine pancreatic kallikrein catalyzed hydrolysis of p-nitroanilides of amino acids was investigated, at pH 8.1 and 37 degrees, in parallel with the effect of ethyl and/or methyl esters of N-benzoyl(-L-)amino acids and benzamidine. For both proteinases, the inhibitory effect of ethyl esters of N-(3- and N-(4-amidinobenzoyl)(-L-)amino acids is independent of the aminoacidic side chain, is closely similar to that of benzamidine (which binds at the S1 subsite of the proteinases examined and is commonly taken as a molecular inhibitor-model), and is higher by at least 10-fold than that of ethyl and/or methyl esters of N-benzoyl(-L-)amino acids (depending on the aminoacidic residue). On structural grounds, the peculiar inhibitory behaviour of ethyl esters of N-(3- and N-(4-amidinobenzoyl)(-L-)amino acids has been related to the interaction of the positively charged substituent at the N-position with the Asp189 residue present in the primary specificity subsite (S1) of bovine trypsin and porcine pancreatic kallikrein. The consistently lower affinity for porcine pancreatic kallikrein of all the inhibitors considered, as compared to bovine trypsin, may be related to the marked structural differences of the primary specificity subsite of these two serine proteinases.
3. N-(cyclohexanecarboxyl)-O-phospho-l-serine, a minimal substrate for the dual-specificity protein phosphatase IphP
P S Savle, T E Shelton, C A Meadows, M Potts, R D Gandour, P J Kennelly Arch Biochem Biophys. 2000 Apr 15;376(2):439-48. doi: 10.1006/abbi.2000.1750.
Three dual-specific phosphatases [DSPs], IphP, VHR, and Cdc14, and three protein-tyrosine phosphatases [PTPs], PTP-1B, PTP-H1, and Tc-PTPa, were challenged with a set of low molecular weight phosphoesters to probe the factors underlying the distinct substrate specificities displayed by these two mechanistically homologous families of protein phosphatases. It was observed that beta-naphthyl phosphate represented an excellent general substrate for both PTPs and DSPs. While DSPs tended to hydrolyze alpha-naphthyl phosphate at rates comparable to that of the beta-isomer, the PTPs PTP-1B and Tc-PTPa did not. PTP-H1, however, displayed high alpha-naphthyl phosphatase activity. Intriguingly, PTP-H1 also displayed much higher protein-serine phosphatase activity in vitro, 0.2-0.3% that toward equivalent tyrosine phosphorylated proteins, than did PTP-1B or Tc-PTPa. The latter two PTPs discriminated between the serine- and tyrosine-phosphorylated forms of two test proteins by factors of >/=10(4)-10(6). While free phosphoserine represented an extremely poor substrate for all of the DSPs examined, the addition of a hydrophobic "handle" to form N-(cyclohexanecarboxyl)-O-phospho-l-serine produced a compound that was hydrolyzed by IphP with high efficiency, i.e., at a rate comparable to that of free phosphotyrosine or p-nitrophenyl phosphate. VHR also hydrolyzed N-(cyclohexanecarboxyl)-O-phospho-l-serine (1 mM) at a rate approximately one-tenth that of beta-naphthyl phosphate. None of the PTPs tested exhibited significant activity against this compound. However, N-(cyclohexanecarboxyl)-O-phospho-l-serine did not prove to be a universal substrate for DSPs as Cdc14 displayed little propensity to hydrolyze it.
Recommended Products
BBF-00703 | Carminomycin I | Inquiry |
BBF-03428 | Tubermycin B | Inquiry |
BBF-05781 | Emodepside | Inquiry |
BBF-00969 | Homomycin | Inquiry |
BBF-03816 | Milbemycin oxime | Inquiry |
BBF-03880 | Cyclopamine | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳